中药注射剂联合降压药治疗高血压肾病:网状Meta分析
本研究系统检索7个中英文数据库至2021年5月的随机对照试验,纳入69项RCT共6373例患者,比较6种中药注射剂联合降压药与单用降压药治疗高血压肾病的疗效与安全性。网状Meta分析显示银杏叶提取物联合双嘧达莫加降压药在降低24小时尿蛋白和收缩压方面最优,丹参多酚酸盐加降压药在降低舒张压方面最优,安全性无显著差异。
要点
- 银杏叶提取物联合双嘧达莫加降压药可能最有效降低24小时尿蛋白和收缩压。
- 丹参多酚酸盐加降压药在降低舒张压方面可能最优。
- 中药注射剂联合降压药与单用降压药安全性无显著差异,但临床需谨慎使用。
核心结论
- 在6种中药注射剂联合降压药中,银杏叶提取物联合双嘧达莫加降压药、丹参多酚酸盐加降压药和丹参酮IIA磺酸钠加降压药可能比单用降压药更有效治疗高血压肾病。
- 鉴于方法学局限性和潜在异质性,临床应谨慎使用各种中药注射剂。
研究设计与样本
- 系统检索PubMed、Embase、Cochrane Library、Web of Science、中国知网、万方和维普数据库,纳入从建库至2021年5月发表的中英文随机对照试验。
- 共纳入69项RCT,6373例患者,涉及6种中药注射剂联合降压药。
- 采用效应模型分析所有结局,使用P-score对每种干预措施排序,并进行敏感性分析、Meta回归和漏斗图检验稳定性、异质性和发表偏倚。
主要发现
- 银杏叶提取物联合双嘧达莫加降压药在降低24小时尿蛋白排泄方面最有效(MD = -0.70,95%CI:-0.82至-0.58;P-score = 1)。
- 银杏叶提取物联合双嘧达莫加降压药在降低收缩压方面最有效(MD = -12.95,95%CI:-21.03至-4.88;P-score = 0.88)。
- 丹参多酚酸盐加降压药在降低舒张压方面最有效(MD = -6.88,95%CI:-10.55至-3.21;P-score = 0.9)。
- 基于主要结局的联合P-score(88%和85.26%)和敏感性分析(72%和71.54%),双标图显示银杏叶提取物联合双嘧达莫加降压药是最有效的干预措施,其次是丹参多酚酸盐加降压药和丹参酮IIA磺酸钠加降压药。
- 中药注射剂联合降压药与单用降压药在安全性方面无显著差异。
关键数值与推荐
- 银杏叶提取物联合双嘧达莫加降压药降低24小时尿蛋白的MD = -0.70(95%CI:-0.82至-0.58),P-score = 1。
- 银杏叶提取物联合双嘧达莫加降压药降低收缩压的MD = -12.95(95%CI:-21.03至-4.88),P-score = 0.88。
- 丹参多酚酸盐加降压药降低舒张压的MD = -6.88(95%CI:-10.55至-3.21),P-score = 0.9。
- 主要结局联合P-score为88%和85.26%,敏感性分析为72%和71.54%。
临床怎么用
- 对于高血压肾病患者,可考虑在降压药基础上联合银杏叶提取物加双嘧达莫、丹参多酚酸盐或丹参酮IIA磺酸钠以改善尿蛋白和血压。
- 临床使用中药注射剂联合降压药时需权衡潜在获益与方法学局限性、异质性和结局差异,谨慎选择。
局限性
- 研究存在方法学局限性和潜在异质性,可能影响结果可靠性。
- 需要更多高质量随机对照试验证实中药注射剂治疗高血压肾病的有效性和安全性。
- 未来研究应关注核心结局的临床价值。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background: Hypertension, a risk factor for cardiovascular events, is often associated with chronic kidney disease. This is called hypertensive nephropathy (HN), which negatively affects physical fitness and body mass, leading to economic burden. Traditional Chinese medicine injections (TCMIs) are common traditional Chinese-patent medicine preparations in China. There was a lack of evidence to prove which TCMIs combine with ADs (TCMIs+ADs) may be a therapeutic option for HN. Thus, we systematically reviewed the efficacy and safety of various TCMIs + ADs in patients with HN. Methods: We conducted a comprehensive search of PubMed, Embase, Cochrane Library, Web of Science, China National Knowledge Infrastructure, Wanfang Data Knowledge Service Platform, and VIP information resource integration service platform databases for relevant Chinese- and English-language randomized controlled trials (RCTs) published from database inception until May 2021. Literature screening, data extraction, and quality assessment was performed by two reviewers independently but using the same criteria. We performed the effect modeling to analyze the data for all outcomes and ranked each intervention using the P-score. Furthermore, sensitivity analysis, meta-regression, and funnel plots were used to test the stability, heterogeneity, and publication bias, respectively. Results: We included 69 RCTs with 6373 patients and including six TCMIs + ADs. Network analysis indicated that the ginkgo leaf extract and dipyridamole combined with ADs (GLED + ADs) was the most efficacious in terms of 24-h urinary protein excretion [mean difference (MD) = -0.70, 95% confidence interval (CI): -0.82 to -0.58; P-score = 1] and systolic blood pressure (MD = -12.95, 95% CI: -21.03 to -4.88; P-score = 0.88), whereas the salvianolate combined with ADs (SA + ADs) showed the highest effectiveness for diastolic blood pressure (MD = -6.88, 95% CI: -10.55 to -3.21; P-score = 0.9). Based on the combined P-score of network meta-analysis results (88% and 85.26%) and sensitivity analysis results (72% and 71.54%), the biplots showed that the GLED + ADs was the most efficacious intervention in all TCMIs + ADs for primary outcomes, followed by the SA + ADs and sodium tanshinone IIA sulfonate combined with ADs (STS + ADs). There was no significant difference in terms of safety between TCMIs + ADs and ADs alone. Conclusion: Of all the TCMIs + ADs, GLED + ADs, SA + ADs, and STS + ADs may demonstrate a higher efficacy than ADs alone for HN. Weighing with the potential benefits and limitations in methodology, potential heterogeneity and outcomes, we should use various TCMIs with caution in clinical practice. Nevertheless, additional high-quality RCTs are warranted and future research should focus on the clinical value of core outcomes to confirm the effectiveness and safety of TCMIs for HN. Systematic Review Registration: clinicaltrials.gov, identifier CRD42020205358.
引用
- Chen Z, Peng Y, Yang F, et al. Traditional Chinese Medicine Injections Combined With Antihypertensive Drugs for Hypertensive Nephropathy: A Network Meta-Analysis. Front Pharmacol. 2021. PMID: 34744724. doi:10.3389/fphar.2021.740821
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。